苦参碱联合5-氟尿嘧啶对人胃癌裸鼠移植瘤的抑制作用

目的　研究苦参碱和5 -氟尿嘧啶(5- FU)联用对人胃腺癌SGC 7901裸鼠移植瘤的抑制作用及骨髓毒性作用。方法　将42只Balb/c小鼠分为阴性对照组(12 只)、5- FU组(6 只)、苦参碱A组(50 mg/kg,6只)、苦参碱B组(100 mg/kg,6只)、联合用药A组(苦参碱50 mg/kg+5 -FU,6只)和联合用药B组(苦参碱100 mg/kg+5 -FU,6只)。观察苦参碱和5 -FU联合用药对胃癌裸鼠移植瘤的抑制作用,计算出相对肿瘤体积(RTV)和肿瘤抑制率(IR);取裸鼠骨髓,计数有核细胞数并进行骨髓集落培养。结果　联合用药B 组抑瘤作用为70. 4%,与其他各组相比疗效明显升高,差异有统计学意义(P<0.01)。与联合用药A组相比,联合用药B组抑瘤作用亦显著增强(P<0.05)。联合用药组对骨髓的抑制作用与5 FU组相比差异无统计学意义(P>0.05)。骨髓集落培养后,与对照组相比,用药组骨髓集落明显生长旺盛。结论　苦参碱和5 -FU联用对人胃癌裸鼠移植瘤的抑制作用明显优于两者单独应用;联合用药对裸鼠骨髓增殖期造血细胞抑制作用有所加重,但不损伤静止期骨髓干细胞。     

芦荟大黄素联合氟尿嘧啶对人胃癌细胞增殖及凋亡的影响

目的 探讨芦荟大黄素(AE)与5-氟尿嘧啶(5-FU)体外协同作用及对人胃癌细胞增殖及凋亡的影响.方法 MTT法检测药物对细胞增殖抑制作用;光镜观察细胞生长状态,计数细胞分裂指数;电镜观察药物对细胞超微结构的影响;TUNEL法检测细胞凋亡.结果 AE单独应用对细胞的增殖抑制作用弱,与5-FU合用明显抑制细胞生长,呈剂量依赖性;药物作用48 h后,联合用药组细胞分裂指数显著降低,可见大量细胞皱缩,胞膜界限模糊,核膜消失,核质浓缩及凋亡小体形成;TUNEL法分析显示,联合用药组细胞凋亡率为(69.4±4.1)%,与AE组[(15.7 4±1.9)%]、5-FU组[(33.5±2.8)%]比较差异显著(P<0.05).结论 AE与5-FU联合应用能有效抑制胃癌细胞增殖,促进细胞凋亡,二药具有协同增效作用.     

顺铂、5-FU联合应用及联用方式对人卵巢癌细胞株生长的抑制作用

采用细胞培养及 MTT方法检测全量、半量顺铂 (DDP)和 5 - FU及各种联用方式如预处置及同时联合应用对人卵巢癌 3AO细胞株的生长抑制作用。结果 :1DDP和 5 - FU对 3AO细胞生长均有显著的抑制作用 (P均 <0 .0 1) ,且 DDP的杀伤作用呈明显的剂量依赖性 ,半量 DDP的抑制作用较全量者明显减弱 (P<0 .0 1) ,而 5 -FU的剂量依赖性作用不明显。 2 DDP和 5 - FU以各种给药顺序、各种浓度方式联合应用对 3AO细胞均有显著的杀伤作用 (P<0 .0 1) ,尤以预处置组作用最为突出。给予 5 - FU全量预处置 2 4h后再给予 DDP(全量 5 - FU预处置组 ) ,对 3AO细胞的抑制率可达 84.8% ,比单用全量 5 - FU或 DDP效果显著提高 (P<0 .0 5 )。5 - FU半量预处置亦显示相同的作用趋势。5 - FU或 DDP半量预处置均可达到单一药物全量所能达到的细胞抑制率。3全量或半量DDP和 5 - FU同时联合应用亦可达到满意的细胞抑制水平。认为 5 - FU和 DDP联合应用及各种联用方式对人卵巢癌 3AO细胞均有显著的杀伤作用 ,尤以 5 - FU预处置的方式作用效果最为明显。采用预处置的方法联合应用DDP和 5 - FU是提高卵巢癌化疗效果、降低单药剂量及毒副作用的新途径。     

尼美舒利和5-氟尿嘧啶联用对胃癌细胞的协同抑制作用及机制

目的 体外研究选择性环氧合酶-2（COX-2）抑制剂尼美舒利和5-氯尿嘧啶（5-FU）对胃癌细胞的抑制作用及机制。方法 以胃癌细胞株MKN45、MKN28为研究对象．观察尼美舒利和5-FU单独或联合应用对细胞增殖、凋亡和细胞周期的影响。应用MTT法检测细胞增殖，流式细胞仪检测细胞凋亡（FITC-Annexin-V/PI双标记）和细胞剧期，RT-PCR观察朋药前后COX-2 mRNA在两株细胞中的表达，Western免疫印迹法观察经两种药物单独和联合作用48h后细胞内凋亡相关蛋白Bax和Bcl-2的表达。结果 在MKN45和MKN28细胞中均可观察到不同水平的COX-2 mRNA表达，尼美舒利和5FU联合应用可明显抑制COX-2 mRNA表达。尼美舒利可抑制两株细胞的增殖并诱导凋亡。尼美舒利和5-FU具有协同抑制细胞增殖及诱导凋亡的作用，该作用与两种药物作用顺序无关，但在联用时作用最强。两药协同抑制增殖的作用主要通过协同杀伤和诱导凋亡而实现。5-FU增强了凋亡诱导蛋白Bax的表达，而尼美舒利则减少凋亡抑制蛋白Bcl-2的表达。两药联用可明显抑制胃癌细胞株生长。结论 选择性环氧合酶-2抑制剂尼美舒利和5-FU通过抑制COX-2 mRNA的表达硬增强Bax／Bcl-2的表达比率诱导胃癌细胞凋亡．从而对胃癌细胞起到协同抑制增殖的作用。     

重组腺病毒Ad-IκBαM在5-氟尿嘧啶诱导胃癌细胞凋亡中的作用

目的:研究重组腺病毒Ad-IκBαM对5-氟尿嘧啶(5-FU)诱导胃癌细胞凋亡的作用情况,进而研究胃癌细胞抵抗5-FU的机制．方法:培养胃癌SGC-7901细胞,感染重组腺病毒Ad-IκBαM的细胞为实验组,感染Ad- IκBα及非感染的空白对照为对照组,以5 mg／L 5-FU加入上述各组细胞,采用EMSA法检测5-FU处理后各组细胞内NF-κB激活情况:应用MTT和TUNEL法分别检测5-FU对各组细胞诱导凋亡的情况．结果:5-FU作用于胃癌细胞可使细胞内NF-κB激活,感染Ad-IκBαM使NF-κB活性受到明显抑制．MTT法证明,5-FU作用后,感染Ad-IκBαM细胞的凋亡(56．36％±0．60％)较感染Ad-IκBα组(47．50％±1．42％)及未感染组(42．95％±1．27％)明显,各组间比较有统计学差异(P≤0．001);TUNEL法结果与MTT相符,感染Ad-IκBαM组的凋亡率为29．7％±2．5％,明显高于感染Ad-IκBα组(20．0％±2．6％)及未感染组(12．3％±1．1％)(P<0．01)．可见,感染Ad- IκBαM可明显提高5-FU诱导的细胞凋亡．结论:感染Ad-IκBαM可通过抑制胃癌细胞NF-κB的活性增强5-FU的诱导凋亡作用．     

壳聚糖-聚天冬氨酸-5氟尿嘧啶纳米粒子对小鼠的抑瘤作用

目的 制备包被壳聚糖-聚天冬氨酸-5氟尿嘧啶(CTS-Pasp-5FU)纳米粒子,观察其对裸鼠人胃癌SGC-7901移植瘤模型的治疗效应和不良反应.方法 通过离子凝胶化反应制备CTS-Pasp-5FU纳米粒子.选择24只裸鼠制备人胃癌SGC-7901移植肿瘤模型,根据注入药物不同均分为CTS-Pasp5FU组、5-FU组和0.9%氯化钠溶液组,观察治疗前和治疗后7、14、21 d药物对肿瘤的治疗效应及骨髓抑制等不良反应.结果 CTS-Pasp-5FU纳米粒子载药率和包封率分别为40.2%和34.9%.治疗后21 d,5-FU组、CTS-Pasp-5FU组肿瘤体积比0.9%氯化钠溶液组明显缩小(P＜0.01);5-FU组、CTS-Pasp-5FU组肿瘤生长抑制率为79.49%、81.10%,瘤重抑制率为65.30%、72.79%,组间比较差异均有统计学意义(P值均＜0.05).与0.9%氯化钠溶液组、CTS-Pasp-5FU组相比,5-FU组骨髓粒细胞-巨噬细胞集落形成单位形成数量明显降低(P＜0.01),总胆红素和ALT明显增高(P＜0.05);白细胞及肌酐水平各组相似(P＞0.05).结论 CTS-Pasp-5FU纳米粒子可显著提高5-FU对肿瘤的抑制作用,并有效降低骨髓抑制等不良反应.     

人大肠癌HCT-8/5-FU耐药细胞株的建立及P-gp测定

目的：建立人大肠癌多药耐药细胞株HCT-8/5- FU及并对其耐药机制进行探讨．方法：先采用较大剂量间歇诱导法进行筛选,再采用浓度梯度递增法作用,历时7mo,至HCT8细胞可长期在5-FU浓度为2．0mg/L的细胞培养液中稳定生长．电镜、HE染色观察2种细胞形态结构差异．体外细胞毒性实验观察他对5-FU ADM,DDP的耐药性．绘制亲本细胞和耐药细胞的体外生长曲线．罗丹明染色法检测其两种细胞P-gp功能表达．结果：HCT-8细胞株经7mo诱导,可在5-FU 2．0 g/L的培养液中稳定增殖,具有多药耐药性,命名为HCT-8/5-FU,该细胞株对5-FU的耐药指数为16．6,并对ADM,DDP有交叉耐药性．该细胞株体外群体倍增时间与亲本细胞差别不显著．HE染色观察耐药细胞胞体较亲本细胞大,细胞核不规则,可见双核、多形核,细胞形态不规则,呈多角形、细长形改变,可见巨核细胞．透射电镜下耐药细胞胞质内线粒体、内质网、溶酶体增多．流式细胞仪罗丹明染色法观察荧光强度曲线左移,提示耐药细胞有过度P-gp表达．结论：成功建立HCT-8/5-FU多药耐药细胞株．先采用较大剂量间歇诱导进行筛选,再采用浓度梯度递增法作用是诱导大肠癌耐药细胞株的较好方式．HCT-8/5-FU细胞株的耐药机制与P-糖蛋白表达有关．     

同源盒基因A13降低胃癌细胞对5-氟尿嘧啶的敏感性及其机制研究

目的探讨同源盒基因A13(HOXA13)表达水平对胃癌细胞5-氟尿嘧啶(5-FU)敏感性的影响及其可能的机制。方法以HOXA13过表达与敲减稳转胃癌细胞株为研究工具,通过药物敏感实验检测HOXA13表达水平改变后,胃癌细胞对5-FU的敏感性有无改变。CCK-8、EdU实验检测HOXA13表达改变后对5-FU细胞增殖抑制作用的影响;流式细胞术检测HOXA13表达下调后对5-FU诱导胃癌细胞凋亡的影响;二代测序探讨HOXA13介导胃癌5-FU耐药的潜在机制。结果HOXA13表达上调后,胃癌细胞5-FU的IC25和IC50升高;下调HOXA13表达能够促进5-FU对胃癌细胞增殖的抑制作用,并促进5-FU诱导的细胞凋亡。ABC转运蛋白通路的激活可能是HOXA13引起胃癌细胞5-FU耐药的潜在机制。结论HOXA13表达异常升高后能够削弱5-FU对胃癌细胞增殖的抑制作用,引起胃癌细胞对5-FU耐药,ABC转运蛋白可能作为重要下游效应分子参与该过程。     

HCTB006联合5-FU对胃癌细胞系MKN28、7901的作用及其机制

目的:探讨肿瘤坏死因子相关诱导配体受体(DR5)的单克隆抗体HCTB006联合5-FU对人胃癌细胞系7901、MKN28的作用以及机制.方法:用ATPlite法检测HBCT006单药组、5-FU单药组及两药物合用对胃癌细胞存活率的影响,研究两者之间的关系;采用流式细胞技术检测胃癌细胞系7901以及MKN28表面DR5的表达水平;Westernblot检测上述3组用药后胃癌细胞内XIAP,caspase3的变化.结果:胃癌细胞系7901、MKN28对HCTB006不敏感;5-FU对二者的增殖抑制作用具有时间以及浓度依赖效应;联合用药组具有很好的协同抑制胃癌细胞系增殖的效果,且具有浓度依赖效应,与给药次序无关.流式细胞技术检测胃癌细胞系7901,MKN28表面死亡受体DR5的表达依次为:93.8%以及87.7%.免疫迹印结果表明,联合用药组可以引发胃癌细胞内凋亡抑制蛋白XIAP的降解,激活最终凋亡执行蛋白caspase3,引起细胞死亡.结论:HTB006与5-FU联合应用具有协同杀伤胃癌细胞的作用.胃癌细胞7901、MKN28对于HCTB006的敏感程度与细胞表面DR5的表达量不相关;联合用药作用机制可能与细胞内抑制凋亡蛋白XIAP降解有关.     

桦褐孔菌的不同提取物对胃癌BGC-823细胞株生长抑制作用的体外观察

目的 研究桦褐孔菌不同提取物对人胃癌BGC-823细胞株生长的抑制作用.方法 制备桦褐孔菌水提取物、石油醚提取物(醚提物)、乙酸乙酯提取物(酯提物)后,采用MTT法,测定3种提取物作用下的胃癌BGC-823细胞株生长的抑制作用.结果 桦褐孔菌水提取物、醚提取物、酯提取物对胃癌BGC-823细胞株的生长均有抑制作用,终浓度在80 g/ml、48 h,体外最大抑制率分别达到51％、60％、62％.结论 桦褐孔菌的石油醚提取物、乙酸乙酯提取物对人胃癌BGC-823细胞株生长抑制作用高于水提取物.     

片仔癀对人结肠癌SW480细胞株的抑制作用研究

目的探究片仔癀对人结肠癌SW480细胞株的抑制效果。 方法通过对人结肠癌SW480细胞株常规体外培养,随机设定空白组、5-氟尿嘧啶（5-FU）组和不同浓度片仔癀组,分别采用对应药物干预24 h、48 h、72 h,并通过细胞增殖活力检测法（MTT法）和荧光显微镜观察其抑制效果。采用人结肠癌SW480细胞株建立结肠癌小鼠模型,把造模成功的150只小鼠随机分为模型组,5-FU组和片仔癀低、中、高剂量组,每组30只;分别以不同剂量药物外敷3 d,通过抑瘤率和原位凋亡检测（TUNEL法）解释抑制效果。 结果1 mg/mL、2 mg/mL、3 mg/mL浓度片仔癀对人结肠癌SW480细胞体外抑制率最高,为70.05%、71.39%、70.12%,与5-FU组比较差异具有统计学意义（χ²=4.49,4.97,4.52;均P<0.05）。4 mg/mL片仔癀抑制率为67.39%,与5-FU组比较差异无统计学意义（χ²=3.57,P>0.05）;荧光显微镜显示5-FU组与片仔癀各组人结肠癌SW480细胞株数量均显示不同程度的减少、体积变小、折光性差、细胞悬浮及脱落死亡。片仔癀高、中、低剂量组对人结肠癌SW480细胞的体内抑瘤率分别为51%、39%、23%,其中高、中剂量组与5-FU组比较差异无统计学意义（χ²=0.05,0.49;均P>0.05）,低剂量组与之比较差异有统计学意义（χ²=4.09,P<0.05）;荧光显微镜显示片仔癀各剂量组和5-FU组对人结肠癌SW480细胞均有不同程度的凋亡反应。 结论片仔癀外用对人结肠癌SW480细胞生长有明显的抑制作用,高、中剂量体内抑制作用与5-Fu相近,优于低剂量,临床可考虑采用高剂量可能取得更佳效果,体外抑制作用上显示则优于5-Fu,但剂量差异影响不大。     

保护性自噬对5-FU诱导的胃癌细胞凋亡的抑制作用

目的:明确5-FU处理胃癌MGC803细胞后自噬的存在,并探讨自噬在5-FU诱导凋亡中的作用.方法:5-FU处理胃癌MGC803细胞.MTT检测细胞增殖能力.流式细胞术检测细胞凋亡.Western blot检测蛋白表达.荧光显微镜观察自噬的发生.结果:0.1-1000mg/L的5-FU作用MGC803细胞48h,抑制细...     

Axitinib alone or in combination with chemotherapeutic drugs exerts potent antitumor activity against human gastric cancer cells in vitro and in vivo

Objective

As the new oral selective VEGFR tyrosine kinase inhibitor, axitinib (AG-013736) exerts powerful antitumor activity in multiple solid tumors, while its’ effect was unclear in gastric cancer. We aimed to investigate the antitumor activity of axitinib alone or combined with chemotherapeutic drugs against human gastric cancer cells in vitro and in vivo.

Methods

The IC₅₀ values of drugs were determined by MTS assay. The median effect of Chou-Talalay was used to assess the synergistic effect of two drugs. Flow cytometry was employed to analyze cell cycle and cell apoptosis. Cell senescence and microvessel density were evaluated by SA-β-gal staining and CD34 staining, respectively. BGC-823-derived xenografts in nude mice were established to investigate the effects of drugs in vivo.

Results

Axitinib alone could inhibit cell proliferation and retard tumor growth through inducing cell cycle arrest at G2/M phase, cell senescence, cell apoptosis, and antiangiogenesis in vitro and in vivo. Axitinib combined with 5-fluorouracil (5-FU) had synergistic inhibitory effect compared to axitinib or 5-FU alone. However, the highest inhibitory effect was found between axitinib and cisplatin (inhibitory ratio >80 % compared to control), which was significantly higher than any single drug (inhibitory ratio for single 5-FU, cisplatin, and axitinib >10, >40, and >40 %, respectively, compared to control) or axitinib combined with 5-FU (inhibitory ratio >50 % compared to control).

Conclusion

We highlighted for the first time that axitinib alone or in combination with 5-fluorouracil or cisplatin has potent antitumor activity against human gastric cancer in vitro and in vivo, which provided solid evidence for future clinical trial.     

Synergistic activity of gamma-linolenic acid and cytotoxic drugs against pancreatic adenocarcinoma cell lines

Background: γ-Linolenic acid (GLA) is growth inhibitory both in vitro and in vivo, at doses non-toxic to non-cancer cells. Chemotherapeutic agents have limited activity in pancreatic cancer. Interactions between GLA and cytotoxic drugs have not previously been investigated; any synergy might improve the therapeutic effect of these agents. Aim: To investigate possible interactions between GLA and 5-fluorouracil (5-FU) or gemcitabine against pancreatic cancer cell lines in vitro. Methods: Two pancreatic cancer cell lines were exposed to GLA alone and in combination with 5-FU or gemcitabine. Residual viable biomass was measured using the MTT assay and the results analysed by the median effect method of Chou and Talalay [Adv Enzyme Regul 1984;22:27–55]. Results: GLA concentrations of 3.9–125 µg/ml had a synergistic or additive growth inhibitory effect on all tested concentrations of gemcitabine. Synergism was demonstrated between GLA and 5-FU only at concentrations of 62.5–125 µg/ml of 5-FU. Conclusion: GLA has a synergistic effect with gemcitabine at concentrations that correspond to in vivo therapeutic doses. GLA with 5-FU is synergistic only at a tight range of high concentrations of 5-FU. GLA lacks toxic side effects and may be useful in combination with gemcitabine.     

Celecoxib attenuates 5-fluorouracil-induced apoptosis in HCT-15 and HT-29 human colon cancer cells

AIM： To investigate the combined chemotherapeutic effects of celecoxib when used with 5-FU in vitro. METHODS： Two human colon cancer cell lines （HCT-15 and HT-29） were treated with 5-FU and celecoxib, alone and in combination. The effects of each drug were evaluated using the MTT （3-（4, 5-dimethylthiazol-2-yl）-2, 5-diphenyltetrazolium bromide） assay, flow cytometry, and western blotting. RESULTS： 5-FU and celecoxib showed a dosedependent cytotoxic effect. When treated with 10-3 mol/L 5-FU （IC50） and celecoxib with its concentration ranging from 10.8 mol/L to 10.4 mol/L of celecoxib, cells showed reduced cytotoxic effect than 5-FU （10.3 mol/L） alone. Flow cytometry showed that celecoxib attenuated 5-FU induced accumulation of cells at subG1 phase. Western blot analyses for caspase-3 and poly （ADP-ribose） polymerase （PARP） cleavage showed that celecoxib attenuated 5-FU induced apoptosis. Western blot analyses for cell cycle molecules showed that G2/M arrest might be possible cause of 5-FU induced apoptosis and celecoxib attenuated 5-FU induced apoptosis via blocking of cell cycle progression to the G2/M phase, causing an accumulation of cells at the GI/S phase. CONCLUSION： We found that celecoxib attenuated cytotoxic effect of 5-FU. Celecoxib might act via inhibition of cell cycle progression, thus preventing apoptosis induced by 5-FU.     

Anti-tumor effect of angiogenesis inhibitor TNP-470 and 5-FU combined therapy on human gastric cancer xenograft

BACKGROUND/AIMS: TNP-470, an angiogenesis inhibitor, has already been used in combination with chemotherapy to enhance its antitumor activity. The mechanism of enhanced antitumor activity in combination therapy has not been clarified, however, and few studies have described the combined effect of TNP-470 and 5-fluorouracil (5-FU) on gastric cancer. The present study was conducted to investigate the effect of TNP-470 + 5-FU on gastric cancer cell line MKN-45 in vivo and in vitro. METHODOLOGY: MKN-45 cells were subcutaneously injected into mice that were divided into 4 groups: a control group, a 5-FU treated group, a TNP-470 treated group, and a 5-FU + TNP-470 treated group. After the inoculation, the volume of subcutaneous tumors was measured. Blood and lymphatic vessels were also analyzed for the assessment of lymphangiogenesis. RESULTS: Compared with 5-FU or TNP-470 alone, the combined effect of TNP-470 and 5-FU significantly inhibited and suppressed tumor growth in a synergistic fashion. The combined therapy significantly suppressed both angiogenesis and lymphagenesis. CONCLUSIONS: The study suggests that the combined therapy provides an enhanced antitumor effect on human gastric cancer. The enhanced antitumor activity is explained mainly by the stronger inhibition of angiogenesis.     

Suppression of P-gp induced multiple drug resistance in a drug resistant gastric cancer cell line by overexpression of Fas

AIM:To observe the drug sensitizing effect and related mechanisms of fas gene transduction on human drug-resistant gastric cancer cell SGC7901/VCR (resistant to Vincristine).METHODS:The cell cycle alteration was observed by FACS. The sensitivity of gastric cancer cells to apoptosis was determined by in vitro apoptosis assay. The drug sensitization of cells to several anti-tumor drugs was observed by MTT assay. Immunochemical method was used to show expression of P-gp and Topo II in gastric cancer cells.RESULTS:Comparing to SGC7901 and pBK-SGC7901/VCR, fas-SGC7901/VCR showed decreasing G2 cells and increasing S cells, the G2 phase fraction of pBK-SGC7901/VCR was about 3.0 times that of fas -SGC7901/VCR but S phase fraction of fas -SGC7901/VCR was about 1.9 times that of pBK-SGC7901/VCR, indicating S phase arrest of fas-SGC7901/VCR. FACS also suggested apoptosis of fas-SGC7901/VCR.fas-SGC7901/VCR was more sensitive to apoptosis inducing agent VM-26 than pBK-SGC7901/VCR. MTT assay showed increased sensitization of fas-SGC7901/VCR to DDP, MMC and 5-FU, but same sensitization to VCR according to pBK-SGC7901/VCR. SGC7901, PBK-SGC7901/VCR and fas -SGC7901/VCR had positively stained Topo II equally. P-gp staining in pBK-SGC7901/VCR was stronger than in SGC7901, but there was little staining of P-gp in fas-SGC7901/VCR.CONCLUSION:fas gene transduction could reverse the MDR of human drug-resistant gastric cancer cell SGC7901/VCR to a degree, possibly because of higher sensitization to apoptosis and decreased expression of P-gp.     

Inhibitory effect of human telomerase antisense oligodeoxyribonucleotides on the growth of gastric cancer cell lines in variant tumor pathological subtype

AIM: To investigate the inhibitory effect of specialized human telomerase antisense oligodeoxyribonucleotides on the growth of well (MKN-28), moderately (SGC-7901) and poorly (MKN-45) differentiated gastric cancer cell lines under specific conditions and its inhibition mechanism, and to observe the correlation between the growth inhibition ratio and the tumor pathologic subtype of gastric cancer cells. METHODS: Telomerase activity in three gastric cancer cell lines of variant tumor pathologic subtype was determined by modified TRAP assay before and after the specialized human telomerase antisense oligodeoxyribonucleotides were dealt with under specific conditions. Effect of antisense oligomer under specific conditions of the growth and viability of gastric cancer cell lines was explored by using trypan blue dye exclusion assay, and cell apoptosis was detected by cell morphology observation, flow cytometry and TUNEL assay. RESULTS: Telomerase activity was detected in well, moderately and poorly differentiated gastric cancer cell lines (the quantification expression of telomerase activity was 43.7TPG, 56.5TPG, 76.7TPG, respectively). Telomerase activity was controlled to 30.2TPG, 36.3TPG and 35.2TPG for MKN-28, SGC-7901 and MKN-45 cell lines respectively after treatment with human telomerase antisense oligomers at the concentration of 5 μmol/L, and was entirely inhibited at 10 μmol/L, against the template region of telomerase RNA component, whereas no inhibition effect was detected in missense oligomers (P<0.05). After treatment with antisense oligomers at different concentrations under specific conditions for 96 h, significant growth inhibition effects were found in MKN-45 and SGC-7901 gastric cancer cell lines (the inhibition ratio was 40.89% and 71.28%), but not in MKN-28 cell lines (15.86%). The ratio of inactive SGC-7901 cells increased according to the prolongation of treatment from 48 to 96 h. Missense oligomers could not lead to the same effect (P<0.05). Apoptosis of SGC-7901 and MKN-45 cells was detected not only by morphology and TUNEL assay but also by flow cytometry. The apoptotic rate reached 33.56% for SGC-7901 cells and 44.75% for MKN-45 cells. CONCLUSION: The viability and proliferation of gastric cancer cells can be inhibited by antisense telomerase oligomers. The growth inhibition of gastric cancer cells is correlated with concentration, time and sequence specialty of antisense oligomers. The inhibition mechanism of antisense human telomerase oligomers depends not only on the sequence specialty but also on the biological characteristics of gastric cancer cell lines.